{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:02:05Z","timestamp":1786114925629,"version":"build-2736575974"},"reference-count":90,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1053\/j.seminhematol.2026.03.009","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:10:43Z","timestamp":1774051843000},"page":"431-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?"],"prefix":"10.1053","volume":"62","author":[{"given":"Christopher S.","family":"Hourigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.009_bib0001","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cyto.990060411","article-title":"Detection of minimal disease in acute leukemia using flow cytometry: studies in a rat model for human acute leukemia","volume":"6","author":"Martens","year":"1985","journal-title":"Cytom: J Int Soc Anal Cytol"},{"key":"10.1053\/j.seminhematol.2026.03.009_bib0002","series-title":"An immunological approach to analyse the kinetics of minimal residual disease in acute leukemia, Minimal Residual Disease in Acute Leukemia 1986","first-page":"76","author":"Hagenbeek","year":"1986"},{"key":"10.1053\/j.seminhematol.2026.03.009_bib0003","first-page":"1","article-title":"Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with 'curability' of experimental leukemia","volume":"35","author":"Skipper","year":"1964","journal-title":"Cancer Chemother Rep"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.009_bib0004","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","article-title":"Minimal residual disease in acute myeloid leukaemia","volume":"10","author":"Hourigan","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.009_bib0005","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/leu.2013.318","article-title":"What does MRD in leukemia really mean?","volume":"28","author":"Goldman","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.009_bib0006","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.seminhematol.2015.04.001","article-title":"Advancing the minimal residual disease concept in acute myeloid leukemia","volume":"52","author":"Hokland","year":"2015","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.009_bib0007","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11899-017-0420-z","article-title":"The prognostic significance of measurable (\"minimal\") residual disease in acute myeloid leukemia","volume":"12","author":"Buccisano","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.009_bib0008","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0009","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.009_bib0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/hematology.2019000060","article-title":"MRD evaluation of AML in clinical practice: are we there yet?, Hematology","volume":"2019","author":"Freeman","year":"2019","journal-title":"Am Soc Hematol Educ Program"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.03.009_bib0011","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0012","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The present and future of measurable residual disease testing in acute myeloid leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.009_bib0013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/hematology.2022000323","article-title":"Achieving MRD negativity in AML: how important is this and how do we get there?","volume":"2022","author":"Hourigan","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.03.009_bib0014","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"138","author":"Cloos","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.009_bib0015","first-page":"676","article-title":"Criteria for the evaluation of response to treatment in acute leukemia","volume":"11","author":"Bisel","year":"1956","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.009_bib0016","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.009_bib0017","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41375-021-01126-3","article-title":"Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia","volume":"35","author":"Paiva","year":"2021","journal-title":"Leukemia"},{"issue":"31","key":"10.1053\/j.seminhematol.2026.03.009_bib0018","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.009_bib0019","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"HemaSphere"},{"issue":"2,Supplement","key":"10.1053\/j.seminhematol.2026.03.009_bib0020","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jtct.2025.01.182","article-title":"Significant Inter-laboratory variability in measurable residual disease multiparameter flow cytometry testing prior to allogeneic transplantation impedes outcome prediction: a CIBMTR analysis","volume":"31","author":"Tettero","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.009_bib0021","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41409-021-01261-6","article-title":"Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation","volume":"56","author":"Percival","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0022","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/s41409-021-01450-3","article-title":"An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis","volume":"56","author":"Jimenez Jimenez","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.009_bib0023","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.009_bib0024","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.009_bib0025","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.009_bib0026","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminhematol.2026.03.009_bib0027","unstructured":"Invivoscribe\u2019s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay, 2025. https:\/\/www.businesswire.com\/news\/home\/20250421272115\/en\/Invivoscribes-LabPMM-Gains-New-York-State-Approval-for-the-FLT3-ITD-MRD-Assay. [Accessed 05.23.25]."},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.009_bib0028","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/bloodadvances.2025016444","article-title":"FLT3-ITD measurable residual disease from the QuANTUM-First trial","volume":"10","author":"Levis","year":"2026","journal-title":"Blood Adv"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.03.009_bib0029","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood BLD"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.03.009_bib0030","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0031","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0032","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1038\/s41375-022-01692-0","article-title":"Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis","volume":"36","author":"Short","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.009_bib0033","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.03.009_bib0034","first-page":"2813","article-title":"How I treat AML incorporating the updated classifications and guidelines","volume":"141","author":"El Chaer","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.03.009_bib0035","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u24c7): acute myeloid leukemia, NCCN Guidelines Version 3.2026 (2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf."},{"issue":"11","key":"10.1053\/j.seminhematol.2026.03.009_bib0036","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.1016\/S1470-2045(25)00426-7","volume":"26","author":"Sanz","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2026.03.009_bib0037","series-title":"Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. Guidance for industry, U.S. Department of Health and Human Services, Food and Drug Administration","author":"Food","year":"2020"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.009_bib0038","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/PPO.0000000000000572","article-title":"MRD assessment as a surrogate marker in new drug development in AML","volume":"28","author":"Gui","year":"2022","journal-title":"Cancer J"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0039","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.009_bib0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.03.009_bib0041","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.2016.67.6395","article-title":"When the minimal becomes measurable","volume":"34","author":"Hourigan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.03.009_bib0042","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0043","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.009_bib0044","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.2025029010","article-title":"Measurable residual disease intervention in AML: a new therapeutic horizon","volume":"147","author":"Wei","year":"2026","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0045","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.009_bib0046","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2025-343","article-title":"Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: a HARMONY alliance study of European randomized trials","volume":"146","author":"Tettero","year":"2025","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.03.009_bib0047","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35960","article-title":"Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium","volume":"131","author":"Boyiadzis","year":"2025","journal-title":"Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.009_bib0048","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/jcm6090087","article-title":"Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia","volume":"6","author":"Roloff","year":"2017","journal-title":"J Clin Med"},{"key":"10.1053\/j.seminhematol.2026.03.009_bib0049","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3389\/fonc.2018.00669","article-title":"Molecular measurable residual disease testing of blood during AML cytotoxic therapy for early prediction of clinical response","volume":"8","author":"Wong","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.009_bib0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.16362","article-title":"Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia","volume":"188","author":"Ghannam","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.009_bib0051","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.2023.283520","article-title":"Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia","volume":"109","author":"Dillon","year":"2024","journal-title":"Haematologica"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.03.009_bib0052","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.009_bib0053","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood.2023022697","article-title":"Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation","volume":"144","author":"Wienecke","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.009_bib0054","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41409-024-02447-4","article-title":"Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.009_bib0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/2643-3230.BCD-21-0046","article-title":"Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from non-malignant clonal hematopoiesis","volume":"2","author":"Dillon","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1053\/j.seminhematol.2026.03.009_sbref0056","article-title":"Genomics of acute myeloid leukemia at diagnosis and remission","author":"Yu","year":"2025","journal-title":"medRxiv"},{"key":"10.1053\/j.seminhematol.2026.03.009_sbref0057","article-title":"Whole genome sequencing informed patient personalized measurable residual disease assays for acute myeloid leukemia","author":"Ravindra","year":"2026","journal-title":"medRxiv"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.009_bib0058","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/bloodadvances.2019001181","article-title":"Single-cell mutational profiling enhances the clinical evaluation of AML MRD","volume":"4","author":"Ediriwickrema","year":"2020","journal-title":"Blood Adv"},{"issue":"7834","key":"10.1053\/j.seminhematol.2026.03.009_bib0059","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.009_bib0060","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.009_bib0061","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cyto.a.22628","article-title":"Single-cell mass cytometry reveals intracellular survival\/proliferative signaling in FLT3-ITD-mutated AML stem\/progenitor cells","volume":"87","author":"Han","year":"2015","journal-title":"Cytom A"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0062","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1038\/s41375-025-02745-w","article-title":"Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution","volume":"39","author":"Karakaslar","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.009_bib0063","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cyto.a.24958","article-title":"Development of a 29-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease and leukemic stem cells in acute myeloid leukemia","volume":"107","author":"Zhang","year":"2025","journal-title":"Cytom A"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.009_bib0064","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.009_bib0065","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41375-024-02300-z","article-title":"Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance","volume":"38","author":"McCarthy","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.009_bib0066","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.22168","article-title":"MAGIC-DR: an interpretable machine-learning guided approach for acute myeloid leukemia measurable residual disease analysis","volume":"106","author":"Shopsowitz","year":"2024","journal-title":"Cytom B Clin Cytom"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.009_bib0067","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2025-6","article-title":"Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","volume":"146","author":"Fathi","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.009_bib0068","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.009_bib0069","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.009_bib0070","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-024-02444-7","article-title":"Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Hegde","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.009_bib0071","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41409-024-02449-2","article-title":"Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.009_bib0072","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-024-02444-7","article-title":"Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Hegde","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.009_bib0073","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41409-025-02757-1","article-title":"Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia","volume":"61","author":"Al-Ali","year":"2026","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.009_bib0074","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3390\/cancers12092339","article-title":"Conditioning intensity, pre-transplant flow cytometric measurable residual disease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"12","author":"Morsink","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.009_bib0075","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"issue":"507","key":"10.1053\/j.seminhematol.2026.03.009_bib0076","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1984","article-title":"Applications of liquid biopsies for cancer","volume":"11","author":"Mattox","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.009_bib0077","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70097","article-title":"Cell-free DNA for detection and monitoring of extramedullary AML relapse","volume":"9","author":"Hupe","year":"2025","journal-title":"Hemasphere"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.009_bib0078","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/bloodadvances.2019001156","article-title":"Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.009_bib0079","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-20589-3","article-title":"Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemia","volume":"15","author":"Sommer","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.009_bib0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000535463","article-title":"Test then erase? Current status and future opportunities for measurable residual disease testing in acute myeloid leukemia","volume":"147","author":"Blackmon","year":"2024","journal-title":"Acta Haematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0081","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.009_bib0082","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.3324\/haematol.2021.279777","article-title":"Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial","volume":"107","author":"Buccisano","year":"2022","journal-title":"Haematologica"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.03.009_bib0083","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1182\/bloodadvances.2024013182","article-title":"Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial","volume":"8","author":"Venditti","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.009_bib0084","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1016\/S2352-3026(25)00037-7","article-title":"Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials","volume":"12","author":"Potter","year":"2025","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.03.009_bib0085","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.2025030816","article-title":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial","volume":"147","author":"Platzbecker","year":"2026","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.03.009_bib0086","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1200\/JCO.23.01599","article-title":"Targeting molecular measurable residual disease and low-blast relapse in aml with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC)","volume":"42","author":"Tiong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.03.009_bib0087","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.009_bib0088","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2022-167837","article-title":"ALLG AMLM26 Phase 1B\/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.009_bib0089","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2024-202895","article-title":"Revumenib as pre-emptive therapy for measurable residual disease in NPM1 mutated or KMT2A-rearranged acute myeloid leukemia: a domain of the multi-arm ALLG AMLM26 intercept platform trial","volume":"144","author":"Loo","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.03.009_bib0090","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1158\/1078-0432.CCR-23-0917","article-title":"The new NCI precision medicine trials","volume":"29","author":"Harris","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T23:42:59Z","timestamp":1785973379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0037196326000223"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.009","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}